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The Expansion of Newborn Screening: Implications
for Public Health and Policy
Leila Barraza*and Lauren Burkhart**
I. INTRODUCTION

Newborn Screening Programs (NBS) have proven to be a successful
model of public health intervention. Shortly after birth, a blood sample is
taken from the heel of newborn babies and tested for certain conditions.
Analysis of the newborn's genome is used at the present time only for confirmation of a positive test from a newborn screen. 2 Whole Genome Sequencing (WGS) of newborns as a routine procedure, however, is the next
progression in the development of newborn screening programs. The reason
for this progression to a whole genome approach, according to the President's Commission on Bioethics, is "because the logic of personalized medicine and of technological progress will inexorably demand it."3 Further, the
interest among parents exists for such a program to develop.4 This article
examines the history of current newborn screening programs and looks beyond into the potential for expansion into WGS as a newborn screening
method. Benefits from WGS of newborns could reap enormous benefits for
public health research for disease prevention and health promotion. Expansion into new scientific areas is never easy and will require a consideration
of ethical and legal constructs and changes in state statutory law. This article looks at policy considerations that will necessarily be examined and addressed for a shift from the current blood spot program to a WGS approach.

*
J.D., M.P.H., Assistant Professor, Mel and Enid Zuckerman College of Public
Health, University of Arizona.
**
J.D., Sandra Day O'Connor College of Law, Arizona State University, 2014.
1.
PRESIDENT'S COUNCIL ON BIOETHICS, THE CHANGING MORAL Focus ON NEWBORN
SCREENING: AN ETHICAL ANALYSIS BY THE PRESIDENT'S COUNCIL ON BIOETHICs 6-7 (2008),

available at
https://repository.library.georgetown.edu/bitstream/handle/10822/548394/
newborn screening.pdf?sequence=1.
2.

See id. at 9.

3.

Id. at 56.

4.
See Aaron J. Goldenberg et al., Parents' Interest in Whole-Genome Sequencing of
Newborns, 16 GENETIC IN MED. 78, 80 (2014). A recent study done of parents throughout the

U.S. found that over seventy percent of parents surveyed would be definitely or somewhat
interested in utilizing WGS if offered through a state's newborn screening program. Id.
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II. NEWBORN SCREENING PROGRAMS

Newborn Screening Programs are essential to public health practice in
the United States. Through NBS programs, early identification and treatment of disease can reduce childhood morbidity and mortality rates by
providing an opportunity for early intervention and treatment.s The Centers
for Disease Control and Prevention (CDC) have recognized NBS as playing
an important role in public health achievements in the first ten years of the
twenty-first century.6
While programs vary between states, newborn screenings generally involve a blood test and a hearing test. The first heel stick blood sample is
performed between twenty-four and forty-eight hours of the newborn's
birth, preferably before the newborn leaves the hospital.8 A second screening is sometimes conducted between ten days and two weeks following
birth, traditionally at the newborn's health care provider's office.9 In some
states, pulse oximetry is performed to test for critical congenital heart disease. 10 Today, state health labs throughout the United States screen approximately four-million babies annually as part of NBS programs." Of these
four-million newborns, close to 12,500 are diagnosed with one of the twenty-nine conditions that are universally tested for in every state through NBS
programs. 12
State NBS programs date back to the early 1960s, when newborn screening was created to test infants for phenylketonuria (PKU).13 PKU is caused
by a gene mutation that that interrupts the enzyme which breaks down phenylalanine, and the subsequent buildup of the substance in the body can

5.
Ctrs. for Disease Control & Prevention, CDC Grand Rounds: Newborn Screening
and Improved Outcomes, 61 MORBIDITY & MORTALITY WKLY. REP. 390, 390 (2012), availa-

ble athttp://www.cdc.gov/mmwr/pdf/wk/mm6121.pdf.
6.
Ctrs. for Disease Control & Prevention, Ten Great Public Health Achievements United States, 2001-2010, 60 MORBIDITY & MORTALITY WKLY. REP. 619, 620 (2011), avail-

able at http://www.cdc.gov/mmwr/pdf/wk/mm6019.pdf.
7.

Nat'l Insts. of Health, How are newborn screening tests done? (reviewed Apr. 12,

2013), http://www.nichd.nih.gov/health/topics/newbom/conditioninfo/Pages/how-done.aspx.
8.
9.

Id.
Id.

10. Nat'l Newborn Screening & Genetics Res. Ctr., NationalNewborn Screening Status
Report (updated Jan. 6, 2013), http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/
nbsdisorders.pdf; How are newborn screening tests done?, supra note 7.
11.
Bill Malone, Newborn Screening at a Crossroads:What Happens if Congress Waits
to Act?, CLINICAL LABORATORY NEWs (2013), http://www.aacc.org/publications

/cln/2013/august/Pages/Newborn-Screening.aspx. The four-million babies screened account
for more than ninety-eight percent of the babies bom in the U.S. CDC Grand Rounds: Newborn Screening and Improved Outcomes, supra note 5.
12.
CDC GrandRounds: Newborn Screening and Improved Outcomes, supra note 5.
13.
PRESIDENT'S COUNCIL ON BIOETHICS, supra note 1, at 1; Malone, supra note 11.
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cause serious defects including permanent severe retardation. 14 Notably, a
special diet absent of this substance allows affected children to entirely
avoid these consequences and live a healthy life."s Early detection is the key
to their health and quality of life. Dr. Robert Guthrie thus developed a
screening test for PKU that involved pricking the foot of a newborn and
collecting and transporting the blood samples on filter paper.
Massachusetts was the first to launch a voluntary newborn screening
program for PKU in 1962, and its program demonstrated the feasibility of
mass screening.1 Multifarious advocacy campaigns led most states to pass
laws mandating PKU screening soon thereafter. Forty-three states had
programs in place by 1973, with panels expanding to include other actionable conditions, and state health departments generally assumed the central
role in the laws' implementation.1 9 The programs' federal support grew
with the passing of federal legislation to support screening in 1976, the establishment of the CDC's Newborn Screening Quality Assurance Program
(NSQAP) in 1978, and the award of federal funding to thirty-four state genetic service programs between 1979 and 1980.20 Federal involvement in
the development of newborn screening programs has continued, with the
NSQAP steadily adding disorders to its program, which is devoted to quality assurance and state public health assistance.21
Though testing for PKU caught on quickly, the expansion of testing for
additional conditions through NBS programs grew slowly. In 2002, the Maternal and Child Health Bureau and the Health Resources Services Administration (HRSA) of the U.S. Department of Health and Human Services
commissioned a report from the American College of Medical Genetics
(ACMG) to analyze the effectiveness of newborn screening, develop recommendations for a uniform list of conditions that should be included, and

14.

Mayo

Clinic,

Phenylketonuria (PKU)

-

Definition

(Nov.

17,

2011),

http://www.mayoclinic.org/diseases-conditions/phenylketonuria/basics/definition/con20026275;

Mayo

Clinic,

Phenylketonuria (PKU)

-

Symptoms

(Nov.

17,

2011),

http://www.mayoclinic.org/diseases-conditions/phenylketonuria/basics/symptoms/con20026275.
15.
Univ. of Wash., See What is the Diet for PKU?, http://depts.washington.edu/
pku/about/diet.html (last visited May 22, 2014).
16.

LORI B. ANDREWS ET AL., GENETICS: ETHICS, LAW & POLICY 381 (3d ed. 2010). The

"Guthrie test" was the prominent method of newborn screening for decades until its recent
widespread replacement with tandem mass spectrometry. Id.
17.
18.
19.

Id.
Id. at 382.
Id.

20.

Id.

21.

U.S. DEP'T OF HEALTH & HUMAN SERVS. ET AL., Newborn Screening Laboratory

Bulletin (Oct. 2008), http://www.cdc.gov/nbslabbulletin/bulletin.html. The NSQAP program
included one disorder at its inception in 1978, eight disorders in 1988, seventeen disorders in
1998, and forty-eight disorders by 2008. Id.
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consider other critical components of achieving positive outcomes for
screened children.2 2 The report, issued in 2005, recommended the use of the
new technology to expand screening capabilities and include more conditions in newborn panels. 23 The most influential part of the ACMG's report
was its "core panel" of twenty-nine conditions, identified as primary screening targets, and its additional twenty-five "secondary targets." 24
The Federal Newborn Screening Saves Lives Act (NSSLA) was passed
in 2008, three years after the ACMG's statement. At the time of its passage,
state-mandated NBS panels still included as few as nine conditions, despite
the ACMG's recommended minimum of twenty-nine.25 The NSSLA expanded the duties of HRSA to take the lead in developing uniform recommendations for screening and to assist states in satisfying these goals. 26
Meeting the HRSA's guidelines was made a prerequisite for receiving certain grant funding to states, made available by the Act for education and
training, development of screening programs, genetic counseling, and postdiagnostic treatment. 27 Finally, the Act assigned the Secretary's Advisory
Committee on Heritable Disorders in Newborns & Children (SACHDNC)
the role of creating a "Recommended Uniform Screening Panel" and a decision-matrix to apply to future disorders in question, and it created an interagency committee to provide guidelines for how the samples and information are handled. 28 The Act is currently up for reauthorization. 29 As of
late May 2014, the Newborn Screening Saves Lives Reauthorization Act of
2013 had passed the U.S. Senate and was referred to the U.S. House Committee on Energy and Commerce.3 0
The SACHDNC's Recommended Uniform Screening Panel consists of
thirty-one disorders.31 Traditionally, testing has only been done for actiona22.

Am. Coll. of Med. Genetics, Newborn Screening: Toward A Uniform Screening

Panel and System 7 (2005), http://www.hrsa.gov/advisorycommittees/mchbadvisory
/heritabledisorders/uniformscreening.pdf; see Michael S. Watson et al., Newborn Screening
Panel and System, 8 GENETICS IN MED. 12S,
12S (2006), available at
https://www.acmg.net/resources/policies/NBS/NBSMainReport 00.pdf.
23.

Newborn Screening: Toward A Uniform Screening Panel and System, supra note

22, at 84.
24. Watson, supra note 22, at 14S.
25.
Malone, supra note 11. Based on the minimal increase in panel size in the three
years following ACMG's statement, federal action appears to be a potentially more effective
catalyst for expansions than the recommendation of persuasive scientific authorities.
26.
See Newborn Screening Saves Lives Act of 2007, Pub. L. 110-204, 122 Stat. 705
(2008).
27.
§ 2, 122 Stat. at 705-6.
28.
§ 4, 122 Stat. at 707.
29.
Newborn Screening Saves Lives Reauthorization Act of 2013, S. 1417, 113th Cong.
(referred to House Committee on Energy and Commerce Subcommittee on Health, Feb. 7,
2014).
30.
31.

Id.
Baby's First Test, About Newborn Screening: Conditions Screened by State,

https://lawecommons.luc.edu/annals/vol23/iss2/5

4

Barraza and Burkhart: The Expansion of Newborn Screening: Implications for Public Healt

Annals of Health Law

Vol. 23

46

ble conditions, such as PKU or hypothyroidism.32 However, there has been
a notable shift in recent years, turning away from screening only if testing
may bring immediate benefit to the child, to an approach of testing for nonactionable conditions. This shift is demonstrated by the inclusion of Cystic
Fibrosis,33 a non-treatable condition that the Cystic Fibrosis Foundation explicitly recommended against including in NBS panels in 1983.34 Though
only six states mandated testing for Cystic Fibrosis just five years ago, all
fifty states now do so. While uniformity of newborn screening programs
has increased overall with federal efforts, state laws surrounding newborn
screening implementation still differ significantly.3 6
All fifty states conduct screening of newborns shortly after birth.3 7 In
2013, state NBS panels ranged from testing for thirty-one to fifty-five conditions, with every U.S. state testing for at least all twenty-nine of the
ACMG's core panel disorders.38 Minnesota and New Jersey mandate the
largest NBS panel, requiring fifty-five conditions to be tested.3 9 These large
panels are a huge and rapid leap from the small six-condition panel used by
forty-six states as recently as ten years ago. 40 The adoption of new technologies, such as tandem mass spectrometry (MS/MS), which allows multiple
conditions to be tested rapidly from the same sample, have been instrumental in the rapid growth of NBS programs. 41
Other than panel size, one key variance among states is the cost to parhttp://www.babysfirsttest.org/newbom-screening/states (last visited May 22, 2014).
32.
See Ctrs. for Disease Control & Prevention, Newborn Screening (updated May 13,
2013), http://www.cdc.gov/ncbddd/pediatricgenetics/newborn-screening.html. While PKU
is mitigated with a special diet, the effects of slowed growth and brain damage that accompany hypothyroidism can be avoided by early use of hormone treatment through medication.
Id. Other conditions that are not as easily treated early, but are included in panels, have secondary benefits from early identification, such as increased protections to compensate for
vulnerability to infection that occurs with sickle cell anemia. Id.
33.

See Cystic Fibrosis Found., Why are Newborns Screenedfor CF? (updated Jan. 31,

2014), http://www.cff.org/AboutCF/Testing/NewbomScreening/ScreeningforCF/.
34.
Lynn M. Taussig et al., Committee Report: Neonatal Screeningfor Cystic Fibrosis,
72 PEDIATRICS 741, 744 (1983).
35.
Why are Newborns Screened for CF?, supra note 33.
36. About Newborn Screening: ConditionsScreened by State, supra note 31.

37.

Suzanne T. Kotkin-Jaszi & John E. Sherwin, Newborn Screening: The Tandem

Mass

Spectrometry

Revolution,

CLINICAL

LABORATORY

NEWs

(2011),

http://www.aacc.org/publications/cln/201 1/June/Pages/NewbomScreening.aspx.
38.
Malone, supra note 11; see National Newborn Screening Status Report, supra note
10; About Newborn Screening: ConditionsScreened by State, supra note 31.
39.
See National Newborn Screening Status Report, supra note 10.
40.
Jeffrey R. Botkin, Whole Genome Sequencing in Newborn Screening: What are we
testing for?, NAT'L HUMAN
GENOME RESEARCH
INST.
(Apr.
25,
2013),

www.genome.gov/Multimedia/Slides/HGP10Symposium/06_Botkin.pdf.
41.
Kotkin-Jaszi & Sherwin, supra note 37. As early as 2011, all forty-nine states that
used MS/MS technology required testing for no fewer than 30 medical conditions. Id. at Fig.
1.
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ents. Currently, fees to newborns' parents range from zero to over $150,
with some states requiring repeat tests or charging by the specimen.42 These
charges do not reflect the full cost of running the panels, which is largely
subsidized by the state and other funding sources. 43
Another key difference between states is the parental requirement to either opt-in or opt-out of newborn screenings. A majority of states allow
parents to opt-out of screenings." In seven states, parents can opt-out for
any reason, while in all but four states the parents may opt-out on religious
grounds.45 The requirement for informed consent also varies, as only eleven
states require parents to be informed of the screening before it occurs, and
only two require consent to be given before testing may commence.46 Additionally, requirements for the storage and use of residual blood samples acquired through newborn screening vary tremendously. 4 7 Three states permit
the destruction of a child's blood sample if requested by that child upon
reaching adulthood. 48 Twenty states have laws that address the retention or
use of residual dried blood samples from newborn screening.49 In four of
those states, the blood samples remain the property of the state. 0 On the
other hand, in ten states, the laws provide specific purposes for which dried
blood sample information may be utilized, including for public health purposes or research. 1

42.

See Nat'l Newborn Screening & Global Res. Ctr., Newborn Screening (updated Oct.

4, 2013), http://genes-r-us.uthscsa.edu/resources/consumer/statemap.htm (click links for individual states). Kansas, Pennsylvania, New York and the District of Columbia offer NBS
free of charge, while Rhode Island charges the highest amount at $157.54. Id. Texas charges
parents per each mandated specimen ($29.50). Id. Arizona, requires two rounds of testing.
Id.
43.
See id.
44.
Michele Caggana et al., Newborn Screening: From Guthrie to Whole Genome Sequencing, 128 PUB. HEALTH REPs. (SUPPLEMENT 2) 14, 16 (2013).

45.
Michelle H. Lewis et al., State Laws Regarding the Retention and Use of Residual
Newborn Screening Blood Samples, 127 PEDIATRICs 703, 707 (2011); PRESIDENT'S COUNCIL
ON BIOETHICS, supra note 1, at 88.

46.
Maryland, Wyoming, and the District of Columbia require informed consent.
PRESIDENT'S COUNCIL ON BIOETHICS, supra note 1, at 89. However, the manner in which these three states require informed consent differs. Maryland requires informed consent through
regulation, while Wyoming and the District of Columbia both require parental consent
through statute. Id. at 89-90, n.10.
47.
A small amount of blood remains on the paper card following a newborn screening,
and this card with the residual blood spot is sometimes stored for future laboratory use. Caggana, supra note 44, at 17.
48.
Michelle H. Lewis et al., State Laws Regarding the Retention and Use of Residual
Newborn ScreeningBlood Samples, 127 PEDIATRICs 703, 707 tbl. 1 (2011).
49.
Id. at 706 tbl. 1.
50.
Id.
51.
Id.
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LEGAL CHALLENGES TO NBS PROGRAMS

The constitutionality of mandating NBS against parents' objections has
been challenged and upheld by the courts. 52 In 2005, Nebraska's Supreme
Court upheld the state's newborn testing program when challenged by parents who claimed that mandatory testing violated their constitutional rights
based on their religious objections.> In the county's action to compel the
parents' compliance, the court, held that the State's interest in infant screening as a means to protect the health and welfare of all children satisfied the
compelling interest standard and was thus constitutional.54
A lawsuit filed in 2009 by twenty-one families against the Minnesota
Department of Health alleged that the collection, use, storage, and dissemination of residual blood spots and test results violated the Minnesota State
Genetic Information Act of 2006 due to a lack of parental consent. 5 The
Minnesota Supreme Court held that use of residual blood spots and test results beyond the initial screening was not authorized by statute. 6 In 2012,
the Minnesota legislature passed a bill requiring all negative test results be
maintained for seventy-one days and then destroyed, unless parental consent to retain the blood spot for a longer period was received. In January
2014, Minnesota settled the lawsuit over its storage and use of newborn
screening residual dried blood spots. 5 As a result of the settlement, the state
began the process of destroying 1.1 million archived blood spots and test
results that had been collected prior to the November 2011 ruling by the
Minnesota Supreme Court. 59 However, in May 2014, the Minnesota legislature passed a bill, repealing the 2012 law, allowing the Department of
Health to keep samples and negative test results indefinitely for certain
newborn screening activities, unless parents provide informed consent revoking authority. 60
A lawsuit filed in Texas challenged the collection of blood spots.6' Five
52. See, e.g., Douglas Cnty. v. Anaya, 694 N.W.2d 601, 608 (Neb. 2005), cert. denied,
546 U.S. 826 (2005).
53.
54.

Id.
Id.

55.
Bearder v. Minn., 806 N.W.2d 766, 769 (Minn. 2011).
56. Id. at 776. The court remanded the case to the district court for further fact finding
in order to determine the appropriate remedy. Id. at 777.
57.
2012 Minn. Sess. Law Serv. Ch. 292 (H.F. 2967) (West, WestlawNext).
58.
Press Release, Minn. Dep't of Health, Lawsuit settlement allows newborn screening
program to move forward (Jan. 13, 2014), http://www.health.state.mn.us/news
/pressrel/2014/newbornscreening0l 1314.html.
59.

Id.

60.
2014 Minn. Sess. Law Serv. Ch. 203 (S.F. 2047) (West, WestlawNext). The new
law becomes effective August 1, 2014. Id.
61.
First Amended Complaint, Beleno v. Tex. Dep't. of State Health Servs., No. SA-09CA-188-FB (W.D. Tex. Sept. 29, 2009), ECF No. 45; Press Release, Parents Sue Texas
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families sued the Texas Department of Health Services and Texas A & M
University System, asserting the collection and storage of newborn blood
samples for research purposes, without parental consent, was an unreasonable search and seizure and violated constitutional principles. 62 The Texas
legislature later enacted a statute requiring that parents be made aware that
their newborn's genetic information may be retained by the Department of
Health Services for research purposes unless the parent, in written form, requests otherwise. 63 The state agreed as part of settling the Beleno case to
destroy approximately five-million blood samples obtained prior to the settlement of the lawsuit. 64
IV.

WHOLE GENOME SEQUENCING

Whole Genome Sequencing, the ability to acquire an individual's entire
set of genetic information with one test, is anticipated to be a "game changer" in medical research and clinical treatment, creating profound implications for science, public health, and law. 65 In 2004, the federal government
set a $1000 goal for sequencing a complete human genome, and that goal
was met even more quickly than the challenge anticipated. The technology
push continues to drive down the time and cost of WGS and bring it closer
to affordable commercial use. 67 In particular, for applications that currently
use genetic testing (such as NBS), sequencing technology will soon be
more efficient and cost-effective than a slew of individual tests that range in
cost from several hundred to several thousand dollars each.
Health Dept. and Texas A&M over Infant Blood Databank (Mar. 18, 2009),
http://www.texascivilrightsproject.org/1096/parents-sue-texas-health-dept-and-texas-amover-infant-blood-databank.
62.
Amended Complaint, supra note 61 at 23; Ann Waldo, The Texas Newborn
Bloodspot Saga has Reached a Sad - and Preventable -

Conclusion, GENOMICs LAW

REPORT (Mar. 26, 2010), http://www.genomicslawreport.com/index.php/2010/03/16/thetexas-newborn-bloodspot-saga-has-reached-a-sad-and-preventable-conclusion.
63.
TEx. HEALTH & SAFETY CODE ANN. §§ 33.0111, 33.018 (West, WestlawNext
through 2013 Third Called Session of the 83rd Legislature).
64.
suit,

Jay Root, Texas officials agree to destroy babies' blood samples after settling lawDALLAS
NEWs
(Feb.
14,
2010),
http://www.dallasnews.com/news/state/

headlines/20091223-Texas-officials-agree-to-destroy-babies-1751.ece.
65.
See Gary E. Marchant & Rachel A. Lindor, The Game Changer: Whole Genome
Sequencing, BIOTECH BRIEFING, Fall 2011, at 3-4, http://www.americanbar.org/content/dam/

aba/publications/emerging-news/biotech-briefingfall201
66.

.authcheckdam.pdf.

Id. at 1-2; Andrew Pollack, The Race to Read Genomes on a Shoestring, Relatively

Speaking, N.Y. TIMES, Feb. 9, 2008, at Cl. In 2012, LifeTechnologies introduced a sequencer that can sequence a whole genome in less than twenty-four hours, for less than $1000.
Press Release, LifeTechnologies, Life Technologies Introduces the Benchtop Ion Proton Sequencer; Designed to Decode a Human Genome in One Day for $1,000 (Jan. 10, 2014),
http://www.lifetechnologies.com/us/en/home/about-us/news-gallery/press-releases/2012/lifetechologies-itroduces-the-bechtop-io-proto.html.html.
67.
Marchant & Lindor, supra note 65, at 2.
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Recognizing these changes, in 2013 the National Institutes of Health
(NIH) granted $5 million each to four recipients to research genomic sequencing and newborn screening disorders."6 ' As of September 2013, the
four grant recipients were researching methods for making newborn information available as a resource for parents and medical providers,69 the benefits of using larger and faster sequencing in Neonatal Instensive Care
Units, 0 the value of additional information gained by exome sequencing of
currently screened disorders, 1 and the ethical, legal, and social implications
for informed consent and the return of results to parents.72 The NIH's large
investment in these grants demonstrates that an expansion of newborn
screening is an influential current consideration, but that issues with such a
proposal have been anticipated and warrant careful research and consideration. Certain organizations, such as the American Academy of Pediatrics
(AAP), have voiced support in favor of mandatory genetic screening of all
newborns.73
V.

HEALTH APPLICATIONS OF WHOLE GENOME SEQUENCING FOR
NEWBORN SCREENING

A. Benefits for Individual Health

The WGS of newborns has the potential to revolutionize disease detection, prevention, and treatment, resulting in radical changes to public health
practice and research. With the use of WGS on newborns, "[p]ersonalized
genomic medicine will then start from the moment of birth, as the [child's
health care provider] will be in possession of a complete map of each young
patient's known genetic defects, vulnerabilities, and susceptibilities." 74 Rare
68.
Nat'l Insts. of Health, News & Events: NIH program explores the use of genomic
sequencing in newborn healthcare (Sept. 4, 2013), http://www.nih.gov/news/health

/sep2013/nhgri-04.htm.
69.
Id. (discussing Brigham and Women's Hospital in Boston, Massachusetts).
70.
Id. (discussing Children's Mercy Hospital in Kansas City, Missouri).
71.
Id. (discussing University of California, San Francisco). Exome sequencing selectively examines only the functionally important sequences of DNA that are translated into
proteins (as opposed to the entire sequence of DNA, of which only 1.5% is actually expressed). See Leah Eisenstadt, What is Exome Sequencing? (Oct. 15, 2010),
http://www.broadinstitute.org/blog/what-exome-sequencing.
72.
News & Events: NIH program explores the use of genomic sequencing in newborn
healthcare,supra note 68 (discussing University of North Carolina at Chapel Hill).
73.
See, e.g., AM. ACAD. OF PEDIATRICS, AAP Issues New Guidance on Genetic Testing
of
Children (Feb.
21,
2013),
http://www.aap.org/en-us/about-the-aap/aap-pressroom/pages/AAP-Issues-New-Guidance-on-Genetic-Testing-of-Children.aspx.
74.
PRESIDENT'S COUNCIL ON BIOETHICS, supra note 1, at 55. Personalized medicine is
an emerging field engendering the concept that medical care can and should be tailored to
the genetic and molecular profile of the individual, and it aims to shift medical practices to
proactive health management and customized care. See generally Edward Abrahams, Geoffrey S. Ginsburg & Mike Silver, The Personalized Medicine Coalition, 5 AM. J.
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genetic disorders that in the past could have led to years of unnecessary
testing and treatment due to misdiagnoses could now be discovered shortly
following a child's birth. Parents may also learn if their child is at an increased risk for certain childhood diseases and implement necessary prevention programs at an early age.
WGS on newborns could impact the individual and population's health
in terms of disease treatment. One significant public health concern - pediatric adverse drug events (ADEs) - would be greatly impacted by a WGS
on newborns. 6 Children are three times more likely to suffer from an ADE
than adults, and over half a million children seek outpatient care for ADEs
annually. The field of pharmacogenomics offers the potential to reduce
ADEs and to enhance the efficacy of pharmaceutical drugs by identifying
gene variants that could affect a person's response to a drug. With a whole
genome in hand at a child's birth, such information may potentially reduce
the number of dangerous pediatric ADEs by providing a personalized
roadmap to how a child may respond to a medication prior to the medication's administration. This is especially important for pediatric cancer patients. Twenty-two percent of all hospital admissions for pediatric cancer
patients are due to an ADE.79 The consequences of an ADE in a pediatric
cancer patient can be life-threatening or leave the patient with long-lasting
disease or disabilities.o Gene variant identification can improve treatment
outcomes for pediatric cancer patients by identifying which patients are at
an increased risk for adverse reactions and manipulating the treatment plan
PHARMACOGENOMICs 345 (2005). Public health genomics is an emerging field that seeks to

utilize genetic variation and gene-environment interaction data to design and implement
mechanisms to prevent disease and improve overall health status. M.J. Khoury et al., A Decade of Public Health Genomics in the United States: Centersfor Disease Control and Prevention 1997 2007, 12 PUB. HEALTH GENOMICs 20, 21 (2009).
75.
See PRESIDENT'S COUNCIL ON BIOETHICS, supra note 1, at 14; see also B.D. Solomon et al., Applying Genomic Analysis to Newborn Screening, 3 MOLECULAR
SYNDROMOLOGY 59, 66 (2012). While positive movement in research and surveillance may
occur, it is also important to note that negative repercussions may result from the WGS of
newborns. PRESIDENT'S COUNCIL ON BIOETHICS, supra note 1, at 70. For example, there is
potential for immense stress and anxiety from false positives or from positive tests for conditions that may never manifest. See id.
76.
See Dennis J. O'Kane et al., Pharmacogenomicsand reducing the frequency of adverse drug events, 4 PHARMACOGENOMICS 1, 3 (2003).
77.
Florence T. Bourgeois et al., PediatricAdverse Drug Events in the Outpatient Setting: An 11-Year NationalAnalysis, 124 PEDIATRICS e744, e747-48 (2009); Donna Woods et
al., Adverse Events and Preventable Adverse Events in Children, 115 PEDIATRICS 155, 158
(2005).
78.
See Colin J.D. Ross et al., Pharmacogenomics of Serious Adverse Drug Reactions
in Pediatric Oncology, 18 J. POPULATION THERAPEUTICS & CLINICAL PHARMACOLOGY e134,
e144 (2011); Dennis J. O'Kane et al., Pharmacogenomics and Reducing the Frequency of
Adverse Drug Events, 4 PHARMACOGENOMICS 1, 1 (2003).
79.
Ross et al., supranote 78, at e134.
80.
Id.
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accordingly."
Similarly, WGS results would be beneficial in relation to toxicogenomics. Toxicogenomics is an emerging technology that would allow scientists to predict whether certain people would be vulnerable to the effects of
certain chemicals.82 From birth, with information from a whole genome sequence, doctors and parents could ensure children were protected from exposure if vulnerability was found and modify a child's environment in response. This protection could continue from birth into adulthood to prevent
unnecessary exposure and risk of potential deleterious health complications.
For example, asbestos exposure led to a dramatic spike in cancerous mesothelioma, but this exposure only affected a fraction of individuals. It was
later discovered that certain genetic traits were linked to development of the
disease, and had that subpopulation been identifiable, avoiding exposure to
the substance could have significantly reduced the cancer incidence.83
Not only could information improve a child's health, but certain results
could also provide needed health information for a child's parent. For example, a child may have inherited a late-onset disorder from a parent, and
the parent may not yet exhibit symptoms at the time of the child's birth.8 4
Such information may aid in the parent's diagnosis and further treatment of
the disorder. 5 This would be most relevant in the early years of a whole genome newborn program, when adults may not have yet had a whole genome
sequence of their own DNA.
The results of WGS may also improve individual disease prevention. By
knowing in advance the diseases a person may be most susceptible to, prevention programs can be targeted to prevent disease development or severity.8 6 For example, in cardiovascular disease, genomics plays a role in dis81.

Id. at el44.

82.
See NAT'L RESEARCH COUNCIL COMM. ON APPLICATIONS OF TOXICOGENoMIC TECHS.
TO PREDICTIVE TOXICOLOGY, APPLICATIONS OF TOXICOGENOMIC TECHNOLOGIES TO
PREDICTIVE TOXICOLOGY AND RISK ASSESSMENT 1 (2007), available at http://www.ncbi.nlm
.nih.gov/books/NBK10209. Toxicogenomics is defined "as the application of genomic technologies (for example, genetics, genome sequence analysis, gene expression profiling, proteomics, metabolomics, and related approaches) to study the adverse effects of environmental
and pharmaceutical chemicals on human health and the environment." Id. at Box 1-1.
83.
See, e.g., Amy Powers & Michele Carbone, The Role of Environmental Carcinogens, Viruses and Genetic Predispositionin the Pathogenesis of Mesothelioma, 1 CANCER
BIOLOGY & THERAPY 348 (2002); Michele Carbone & Haining Yang, Molecular Pathways:
Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma, 18
CLINICAL CANCER RESEARCH 598 (2012).
84.
0. M. Vanakker & A. De Paepe, Pharmacogenomicsin Children:Advantages and
Challenges of Next Generation Sequencing Applications, 2013 INT'L J. PEDIATRICS 1, 7

(2013).
85.
86.

Id.
See Bonnie Rochman, Will my son develop cancer? Sequencing your kids' genomes

(updated Oct. 22, 2012, 10:05 AM), http://www.cnn.com/2012/10/22/health/sequencechildren-genomes/index.html. While such testing may have the potential to provide predic-
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ease prediction and identification of therapeutic targets. Identification of
certain genetic markers has already been associated with cardiovascular
disease, and whole genomic sequencing could identify genes with previously unknown roles in the development of cardiovascular disease. Additionally, genetic variant identification indicating an increased risk of cancer is
now being utilized to influence disease screening, disease risk counseling,
and preventive treatments.89 In addition to disease prevention, WGS can be
used to predict prognosis and treatment response in certain cancers. 90
A reduction of risk from a common disease, such as cardiovascular disease, could affect many millions of individuals throughout the population.91
In addition to the traditional focus on the risk of developing common diseases, the field of public health genomics could find dramatic success by
expanding the focus to rare diseases.92 This expansion could potentially
identify millions of individuals who unknowingly carry mutations that predispose them to preventable disease. 93 One such example is Lynch syndrome.94 Approximately 0.2% of individuals in the U.S. carry deleterious
genetic mutations in any one of the four genes associated with Lynch syndrome. 95 These individuals are at a greater than 80% risk for colon cancer.96
Knowing such cumulative information at a child's birth could lead to dramatic increases in disease prevention.
B.

Benefits to PopulationHealth

Besides benefits to the individual child or his parents, WGS of newborns
could lead to advances in population health. The population's health as a
tive results, some evidence has shown that current genomic profiling for disease risk may not
be as effective as previously anticipated. See Glenn E. Palomaki et al., Use of Genomic Panels to Determine Risk of Developing Type 2 Diabetes in the General Population:a Targeted
Evidence-BasedReview, 15 GENETICS MED. 600, 609 (2013). This may improve, however, as
research continues to evaluate combinations of genomic markers. See, e.g., Glenn E. Palomaki et al., Use of genomic profiling to assess risk for cardiovasculardisease and identify
individualized prevention strategies A targeted evidence-based review, 12 GENETICS MED.

772,782 (2010).
87.
Santhi K. Ganesh et al., Genetics and Genomics for the Prevention and Treatment
of CardiovascularDisease: Update: A Scientific Statementfrom the American HeartAssociation, 128 CIRCULATION 2813,2813 (2013).
88.
Id.
89.
Cinnamon S. Bloss et al., Genomics for Disease Treatment and Prevention, 34
PSYCHIATRIC CLINICS

N. AM. 147, 154-55 (2011).

90.
Id. at 157.
91.
James Evans et al., We screen newborns, don't we?: realizing the promise of public
health genomics, 15 GENETICS MED. 332, 332 (2013); see Ganesh, supra note 87, at 2814-17.

92.

Evans, supra note 91, at 332.

93.
94.
95.
96.

Id.
Id.
Id.
Id.
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whole could benefit through research of disease trends through surveillance
from data collected as a result of WGS of newborns. 97 Public health researchers could not only survey the current status of disease patterns, but
also be able to research future population health needs. 98 Funding could be
allocated to research diseases for which large groups of the population are
known to be at risk. Instead of retrospective research of disease, studies
could be done prospectively to advance further disease treatment.
Standardizing newborn WGS also has the potential to reduce health disparities throughout the population by improving and equalizing care. In particular, though all states are required to meet a federal minimum panel, most
states have added additional conditions to their screenings. Thus, currently,
children born in particular states receive more information than children located in a state testing for a smaller number of conditions. If WGS is implemented as the standard for population-wide newborn screening, its benefits would not be limited to certain residents in particular states or to those
that can afford genomic testing. 99
VI.

POLICY CONSIDERATIONS FOR FUTURE IMPLEMENTATION OF A WGS
APPROACH

All fifty states maintain a newborn screening program and statutory and
regulatory laws govern how the programs operate. An overhaul of state law
will therefore be necessary for a WGS newborn screening approach to exist.
For certain disorders, such as PKU, current newborn screening testing may
be more accurate than a DNA-based testing. 00 Therefore, WGS may be implemented alongside current newborn bloodspot screening, rather than replace it.o 1 It may also be implemented in a manner allowing parents to select the WGS of their newborn child, in addition to the traditional heel stick
exam. 102
97.
Public health surveillance allows the public health community to monitor infectious
and noninfectious diseases, birth defects, injuries, illicit drug use, mental illness, and occupational and environmental exposures. James W. Buehler, Introduction, 61 MORBIDITY &
MORTALITY WKLY. REP. (SUPPLEMENT) 1, 1 (2012), available at http://www.cdc.gov/
mmwr/pdf/other/su6103.pdf.
98.
See Lawrence 0. Gostin & James G. Hodge, Jr., Genetic Privacy and the Law: An
End to Genetics Exceptionalism, 40 JURUIETRICs 21, 39 (1999) ("Carefully planned surveillance or epidemiological activities facilitate rapid identification of health needs.").
99.
See, e.g., Mark A. Rothstein, The Case Against Precipitous, Population Wide,
Whole-Genome Sequencing, 40 J. L. MED. & ETHICs 682, 685 (2012) (explaining the concern

for a lack of equitable access to genetic services when implementing population-wide whole
genome sequencing).
100.
Beth A. Tarini & Aaron J. Goldenberg, Ethical Issues with Newborn Screening in
the Genomics Era, 13 ANN. REv. GENOMICS & HUM. GENETICs 381, 389 (2012).

101.
102.

Id.

See Yuval E. Landau et al., Genomics in Newborn Screening, 164 J. PEDIATRICS
14, 18 (2014); see also How are newborn screening tests done?, supra note 7 (explaining the
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Lessons from the legal challenges and constraints from current newborn
screening programs can guide policymakers in the development of necessary statutory changes in order to implement a WGS approach to newborn
screening. Some of the issues that will need to be studied and considered
include informed consent, the reporting of results, the storage, ownership,
and use of genetic samples and data, privacy, and the constitutionality of a
WGS mandate.
A.

Informed Consent

While all states mandate newborn screening, a majority of states allow
parents to opt-out of screenings if they object on religious or philosophical
grounds. 103 Although the AAP supports mandatory genetic screening for all
newborns, the AAP recommends parents be given the right to refuse newborn screening following information on benefits and risk of genetic testing
and screening.104 Most states do not currently require informed consent prior to the screening, and only approximately half of states require parents be
given educational materials pertaining to the screening.105 With the shift to
WGS, more states may need to structure mandatory newborn screening
programs to include an informed consent requirement and education regarding the results.106 Information may include the risks to the actual testing, the
WGS process, and the potential results in terms of genomic disorders and
determination of disease risk.
B.

Reporting of Results

One overarching legal and ethical issue when dealing with newborn
health information includes deciding what information to provide to the
newborn's parents and how specifically to deliver the information to the
parents, especially if such information provides negative health consequences. Policymakers would need to consider whether results would include late or adult onset disorders, or only disorders for which a childhood
onset manifests. The AAP currently discourages the practice of reporting
late-onset disorders discovered through whole genome newborn screening.10 7 In the ACMG's recommendations for reporting of incidental findings, however, the ACMG felt that the ethical concerns about providing the
clinicians of children with genetic risk information about adult-onset dis-

traditional process used for screening).
103.
Botkin, Whole Genome Sequencing in Newborn Screening, supra note 40.
104.
AM. ACAD. OF PEDIATRICS, supra note 73.
105.
PRESIDENT'S COUNCIL ON BIOETHICS, supra note 1, at 89; Tarini & Goldenberg,
supra note 100, at 385.
106.
See 0. M. Vanakker & A. De Paepe, supra note 84, at 6.
107.
AM. ACAD. OF PEDIATRICS, supra note 73.
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eases were outweighed by the potential benefit to the future health of the
child and the child's parent of discovering an incidental finding for which
intervention might be possible.0s Thus, the ACMG recommended the reporting of incidental findings "not be limited by the age of the person being
sequenced."1 09
C.

Storage, Ownership, and Use

Another crucial consideration will be the issue of storage, ownership, and
use of the samples and increased amount of genetic data gained from
WGS." 0 The storage and use of residual blood spots are of prevailing debate and litigation, and the use of WGS will add an advanced dimension to
the controversy, especially considering the increased amount of personal
information that will be contained in the results. Policymakers would need
to examine such issues as whether the state should retain genetic data generated from WGS for use in future research, and if so, whether an opt-in or
opt-out approach for parents to decide if their newborn's data could be utilized for future research would be most appropriate." Further considerations include who shall gain ownership over the samples and resulting data
(possibly the state itself); the type and number of entities that will be granted access to the data for research purposes; how long the data should be
maintained; and who should maintain oversight of the data.112
D.

Privacy

Privacy of health information is of preeminent concern. Genetic information has the potential for abuse, and information about a newborn's
health could negatively follow the child throughout their lifetime.113 This
concern for the protection of the privacy of genetic information has been
reviewed and studied extensively. 114 While privacy should be an issue to be
taken into thorough consideration in the development of a WGS approach
to newborn screening, the authors would like to focus on one aspect of the
108.
Robert Green et al., ACMG recommendationsfor reporting of incidentalfindings
in clinicalexome and genome sequencing, 15 GENETICS MED. 565, 568 (2013).
109.
Id. The ethical and legal issues pertaining to the return of results from newborn
screenings are included in one of the aforementioned NIH funded grant projects.
110.
See Jeffrey R. Botkin et al., Retention and Research Use of Residual Newborn
Screening Bloodspots, 131 PEDIATRICS 120, 122-25 (2013); John A. Robertson, The $1000
Genome: Ethical and Legal Issues in Whole Genome Sequencing of Individuals, 3 AM. J.

W35, W37 (2003).
Id.
Id.
See, e.g., Yuval E. Landau et al., supra note 102, at 18.
See, e.g., Gostin & Hodge, Jr., supra note 98; PRESIDENTIAL

BIOETHICS

111.
112.
113.
114.

STUDY OF BIOETHICAL ISSUES, PRIVACY AND PROGRESS IN WHOLE

COMM. FOR THE
GENOME SEQUENCING

(2012), available at http://bioethics.gov/sites/default/files/PrivacyProgress508_1.pdf.
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discussion: de-identification. While a recent survey found that a majority of
parents would be interested in utilizing WGS for newborns, interest
dropped when parents were presented with the potential for de-identified
data generated from the WGS to be stored and used for research in the future.115 De-identification, used often for use in future research, separates
any linkable identifiable information from the data. A usable standard for
the de-identification of health information comes from the Health Insurance
Portability and Accountability Act of 1996 (HIPAA) Privacy Rule, which
finds that de-identification occurs when "there is no reasonable basis to believe that the information can be used to identify an individual." 16 Along
with the consideration for the storage of genetic data, policymakers will
need to consider policies to ensure privacy is maintained and, specifically,
whether any stored data should be maintained in an identified or deidentified manner.
E.

Constitutionalityof Mandate

Lastly, newborn screening programs are lawfully mandated under states'
parens patriae power, which provides the states with power to protect the
well-being of children or other groups of a diminished capacity, based on
the fact that they cannot adequately protect themselves." In addition, public health measures can survive scrutiny based on constitutional challenges,
such as alleged Fourth Amendment violations of unreasonable search and
seizure in the context of blood draws, if the government interest justifies the
intrusion on the right. Since the seminal Jacobson v. Massachusetts, when
the government can demonstrate a public health interest, it may take action
that is proportional to the benefits and minimizes harm to others.11 9 The
115.
Aaron J. Goldenberg et al., Parents' interest in whole-genome sequencing of newborns, 16 GENETICS MED. 78, 82 (2014).
116.
In addition, the HIPAA Privacy Rule allows covered entities to disclose protected
health information to public health authorities, without authorization, for general public
health activities, including conducting public health surveillance. See 45 C.F.R. §§
164.514(e)(1)(i), 164.512(b)(1)(i) (West, through May 15, 2014; 79 Fed. Reg. 27,771); U.S.
Dep't of Health & Human Servs., Health Information Privacy: Pub. Health (revised Apr. 3,
2003), http://www.hhs.gov/ocr/privacy/hipaa/understanding/special/publichealth/index.html
(stating that covered entities include health care providers, health care clearinghouses, and
health plans); U.S. Dep't of Health & Human Servs., For Covered Entities and Business Associates,
http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/index.html
(last visited May 22, 2014).
117.
See Botkin, Retention and Research Use of Residual Newborn Screening Bloodspots, supra note 110.
118.

See JAMES G. HODGE, JR., PUBLIC HEALTH LAW IN A NUTSHELL 35 (2014) ("[A]

state may serve as guardian of, or provide protections for, persons who may otherwise lack
capacity to look after their own interests or welfare."); Tarini & Goldenberg, supra note 100,
at 384; Jennifer Kraszewski et al., Legal Issues in Newborn Screening: Implicationsfor Public Health Practiceand Policy, 121 PUB. HEALTH REP. 92, 93 (2006).
119.
Jacobson v. Mass., 197 U.S. 11, 25-27 (1905).
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government's interest in public health and welfare has long since been recognized as justifying invasive measures that proportionally benefit the population's health.120 Thus, expanding newborn screening to include the whole
genome would be constitutionally valid so long as the expansive cumulative
benefits of such an expansion are deemed greater.
VII. CONCLUSION

It is easy to postulate about the revolutionary changes a WGS newborn
screening approach could have on future research and individual and population health outcomes. Such changes could include early diagnoses of genetic disorders prior to the child becoming symptomatic. Research programs and research funding could prospectively be targeted to certain
disorders for which a large percentage of the population is at risk. If a WGS
approach to newborn screening is to co-exist or replace the traditional heel
stick blood spot newborn screening programs currently in existence, numerous legal changes will need to examined and implemented. Statutory
and regulatory codes will need to be amended and adjusted for the inclusion
of routine gathering of genetic information through newborn screening. Policymakers can use prior legal challenges to existing newborn screening programs as a model for developing sound legal and ethical policies for future
realization of a WGS approach to newborn screening

120.
See id. See also LAWRENCE 0. GOSTIN, PUBLIC HEALTH LAW: POWER, DUTY,
RESTRAINT 126-28 (2nd ed. 2008) (stating that public health powers are constitutionally permissible if exercised in agreement with the following five standards: public health necessity,
reasonable means, proportionality, harm avoidance, and fairness).
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